Milnacipran is a dual serotonin-norepinephrine  reuptake inhibitor (SNRI) in use in Europe, Asia and Australia. Its norepineprine:serotonin effects are 3:1, in contrast to other SNRIs (e.g. venlafaxine, with a 1:30 norepineprine:serotonin ratio).